Literature DB >> 6132838

Adenosine deaminase normalizes cyclic AMP responses of hypothyroid rat fat cells to forskolin, but not beta-adrenergic agonists.

C C Malbon, M P Graziano.   

Abstract

Lipolysis and cyclic AMP accumulation in response to beta-adrenergic agonists or forskolin are severely impaired in fat cells from the hypothyroid rat. Incubating hypothyroid rat fat cells with adenosine deaminase normalizes the cyclic AMP response to forskolin, but not to beta-adrenergic agonists. Increased sensitivity to adenosine action in the hypothyroid state appears to be the basis for the impaired cyclic AMP response to forskolin, but does not appear to be the underlying defect responsible for the impaired response to beta-adrenergic agonists.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6132838     DOI: 10.1016/0014-5793(83)80203-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  Enzymes involved in adenosine metabolism in rat white and brown adipocytes. Effects of streptozotocin-diabetes, hypothyroidism, age and sex differences.

Authors:  Z Jamal; E D Saggerson
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

2.  Thyroid status and adenosine content of adipose tissue.

Authors:  J J Ohisalo; S Stoneham; L Keso
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

3.  Sensitivity of adipocyte lipolysis to stimulatory and inhibitory agonists in hypothyroidism and starvation.

Authors:  E D Saggerson
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

4.  Effect of adenosine deaminase, N6-phenylisopropyladenosine and hypothyroidism on the responsiveness of rat brown adipocytes to noradrenaline.

Authors:  J A Woodward; E D Saggerson
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

Review 5.  The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review).

Authors:  Kuo Yan; Li-Na Gao; Yuan-Lu Cui; Yi Zhang; Xin Zhou
Journal:  Mol Med Rep       Date:  2016-03-18       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.